(Q36492347)

14 August 2017

1 reference

title

Emerging therapeutics for Alzheimer's disease. (English)

1 reference

14 August 2017

0 references

Nigel M Hooper

3

0 references

author name string

Emma R L C Vardy

series ordinal

1

1 reference

14 August 2017

Ishrut Hussain

series ordinal

2

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

14 August 2017

published in

1 reference

14 August 2017

volume

6

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

695-704

1 reference

Treatment of Alzheimer's disease: current status and new perspectives.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

RIPped out by presenilin-dependent gamma-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Regulation of APP cleavage by alpha-, beta- and gamma-secretases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Gleevec inhibits β-amyloid production but not Notch cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

JLK isocoumarin inhibitors: selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Pharmacological strategies for the prevention of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Neuronal membrane cholesterol loss enhances amyloid peptide generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Cholesterol in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Neprilysin regulates amyloid Beta peptide levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Analysis of the subsite specificity of rat insulysin using fluorogenic peptide substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Strategies for disease modification in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Alzheimer's disease: Abeta, tau and synaptic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Tau protein phosphorylation as a therapeutic target in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

GSK3 inhibitors: development and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Cell mediators of inflammation in the Alzheimer disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Clinical trials. Halt of Celebrex study threatens drug's future, other trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

Pathology and pathways of Alzheimer's disease with an update on new developments in treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.695

21 January 2018

Identifiers

DOI

10.1586/14737175.6.5.695

1 reference

14 August 2017

1 reference